Landec Corporation is a leading innovator of diversified health and wellness solutions with two operating businesses: Curation Foods, Inc. and Lifecore Biomedical, Inc.Landec designs, develops, manufactures and sells products for the food and biopharmaceutical industry. Curation Foods is focused on innovating and distributing plant-based foods with 100% clean ingredients to retail, club and foodservice channels throughout North America. Curation Foods is able to maximize product freshness through its geographically dispersed family of growers, refrigerated supply chain and patented BreatheWay® packaging technology. Curation Foods brands include Eat Smart® fresh packaged vegetables and salads, O Olive Oil & Vinegar® premium artisan products and Yucatan® and Cabo Fresh® avocado products. Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes and vials. As a leading manufacturer of premium, injectable grade Hyaluronic Acid, Lifecore brings 35 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
Company profile
Ticker
LFCR
Exchange
Website
CEO
Albert Bolles
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LANDEC CORP \CA\
SEC CIK
Corporate docs
Subsidiaries
Curation Foods, Inc. • Lifecore Biomedical, Inc. ...
IRS number
943025618
LFCR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results
16 Mar 23
10-Q
2023 Q2
Quarterly report
16 Mar 23
10-K/A
2022 FY
Annual report (amended)
16 Mar 23
8-K
Departure of Directors or Certain Officers
3 Mar 23
8-K
Entry into a Material Definitive Agreement
7 Feb 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
31 Jan 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Jan 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
NT 10-Q
Notice of late quarterly filing
9 Jan 23
Transcripts
LFCR
Earnings call transcript
2023 Q1
6 Oct 22
LFCR
Earnings call transcript
2022 Q4
11 Aug 22
LFCR
Earnings call transcript
2022 Q3
6 Apr 22
LFCR
Earnings call transcript
2022 Q2
6 Jan 22
LFCR
Earnings call transcript
2021 Q4
29 Jul 21
LFCR
Earnings call transcript
2021 Q3
8 Apr 21
LFCR
Earnings call transcript
2021 Q2
6 Jan 21
LFCR
Earnings call transcript
2021 Q1
7 Oct 20
LFCR
Earnings call transcript
2020 Q4
11 Aug 20
LFCR
Earnings call transcript
2020 Q3
31 Mar 20
Latest ownership filings
SC 13D/A
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
16 Mar 23
SC 13D/A
WYNNEFIELD PARTNERS SMALL CAP VALUE LP
7 Mar 23
SC 13G/A
ISZO CAPITAL LP
14 Feb 23
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
10 Feb 23
4
Christopher S Kiper
2 Feb 23
4
JEFFREY L EDWARDS
2 Feb 23
4
LOVAS KATRINA HOUDE
2 Feb 23
4
NELSON OBUS
2 Feb 23
4
Nathaniel Calloway
2 Feb 23
4
Joshua Schechter
2 Feb 23
Financial summary
| Quarter (USD) | Nov 22 | Aug 22 | May 22 | Feb 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | May 22 | May 21 | May 20 | May 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 6.83 mm | 6.83 mm | 6.83 mm | 6.83 mm | 6.83 mm | 6.83 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 4.15 mm | 7.24 mm | 982.67 k | 2.05 mm |
| Cash used (since last report) | n/a | n/a | 16.55 mm | 28.87 mm | 3.92 mm | 8.17 mm |
| Cash remaining | n/a | n/a | -9.72 mm | -22.04 mm | 2.91 mm | -1.34 mm |
| Runway (months of cash) | n/a | n/a | -2.3 | -3.0 | 3.0 | -0.7 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 95 |
| Opened positions | 11 |
| Closed positions | 4 |
| Increased positions | 34 |
| Reduced positions | 28 |
| 13F shares | Current |
|---|---|
| Total value | 129.50 bn |
| Total shares | 30.02 mm |
| Total puts | 34.70 k |
| Total calls | 3.20 k |
| Total put/call ratio | 10.8 |
| Largest owners | Shares | Value |
|---|---|---|
| Wynnefield Capital | 4.46 mm | $28.92 bn |
| Wynnefield Partners Small Cap Value LP I | 3.21 mm | $26.84 mm |
| Legion Partners Asset Management | 2.94 mm | $19.05 bn |
| Cove Street Capital | 1.95 mm | $12.61 mm |
| BLK Blackrock | 1.85 mm | $11.98 bn |
| Dimensional Fund Advisors | 1.76 mm | $11.39 mm |
| 22NW Fund | 1.76 mm | $18.43 mm |
| 22NW | 1.76 mm | $11.37 bn |
| Vanguard | 1.27 mm | $8.25 bn |
| Heartland Advisors | 1.20 mm | $7.79 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Feb 23 | Schechter Joshua | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,554 | 0.00 | 9,554 |
| 1 Feb 23 | Raymond H Diradoorian | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,554 | 0.00 | 9,554 |
| 1 Feb 23 | Craig A. Barbarosh | RSU Common Stock | Grant | Acquire A | Yes | No | 0 | 9,554 | 0.00 | 9,554 |
| 1 Feb 23 | Houde Lovas Katrina | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,554 | 0.00 | 9,554 |
| 1 Feb 23 | Nelson Obus | RSU Common Stock | Grant | Acquire A | No | No | 0 | 9,554 | 0.00 | 9,554 |
News
Analyst Ratings for Lifecore Biomedical
21 Mar 23
Barrington Research Maintains Outperform on Lifecore Biomedical, Lowers Price Target to $8
21 Mar 23
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
20 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 20, 2023
20 Mar 23
Lifecore Biomedical, Inc. - Common Stock's Return On Capital Employed Insights
20 Mar 23
Press releases
Lifecore Biomedical Signs Term Sheet with Existing Long-Term Customer to Expand CDMO Relationship
16 Mar 23
Lifecore Biomedical Announces Intent to Explore Strategic Alternatives
16 Mar 23
Lifecore Biomedical Reports Second Quarter Fiscal Year 2023 Results
16 Mar 23
Lifecore Biomedical Announces Sale of Curation Foods' Avocado Products Business
7 Feb 23
Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report
11 Jan 23